Laboratory of America Holdings Key Executives
This section highlights Laboratory of America Holdings's key executives, including their titles and compensation details.
Find Contacts at Laboratory of America Holdings
(Showing 0 of )
Laboratory of America Holdings Earnings
This section highlights Laboratory of America Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-04-29 | $3.73 | $2.52 |
| Read Transcript | Q4 | 2024 | 2025-02-06 | $3.39 | $3.45 |
| Read Transcript | Q3 | 2024 | 2024-10-24 | $3.47 | $3.50 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $3.78 | $3.94 |
| Read Transcript | Q1 | 2024 | 2024-04-25 | $3.48 | $3.68 |
| Read Transcript | Q4 | 2023 | 2024-02-15 | $3.29 | $3.30 |
| Read Transcript | Q3 | 2023 | 2023-10-26 | $3.37 | $3.38 |
| Read Transcript | Q2 | 2023 | 2023-07-27 | $3.47 | $3.42 |
| Read Transcript | Q1 | 2023 | 2023-04-25 | $3.99 | $3.82 |
Financial Statements
Access annual & quarterly financial statements for Laboratory of America Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $13.01B | $12.16B | $14.88B | $16.12B | $13.98B |
| Cost of Revenue | $9.51B | $8.80B | $10.49B | $10.50B | $9.03B |
| Gross Profit | $3.50B | $3.36B | $4.39B | $5.62B | $4.95B |
| Gross Profit Ratio | 26.92% | 27.67% | 29.48% | 34.89% | 35.43% |
| Research and Development Expenses | $- | $2.00M | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $2.23B | $2.02B | $2.00B | $1.95B | $1.73B |
| Other Expenses | $166.30M | $615.90M | $259.30M | $369.60M | $275.40M |
| Operating Expenses | $2.40B | $2.64B | $2.26B | $2.32B | $2.00B |
| Cost and Expenses | $11.90B | $11.44B | $12.75B | $12.82B | $11.03B |
| Interest Income | $- | $- | $8.90M | $10.20M | $10.30M |
| Interest Expense | $208.30M | $199.60M | $180.30M | $212.10M | $207.40M |
| Depreciation and Amortization | $643.50M | $577.30M | $537.20M | $940.00M | $825.00M |
| EBITDA | $1.81B | $1.35B | $1.95B | $4.28B | $3.25B |
| EBITDA Ratio | 13.92% | 11.10% | 13.14% | 26.54% | 23.26% |
| Operating Income | $1.11B | $725.60M | $1.77B | $3.26B | $2.45B |
| Operating Income Ratio | 8.50% | 5.97% | 11.92% | 20.22% | 17.49% |
| Total Other Income Expenses Net | $-146.30M | $-156.70M | $-199.10M | $-132.90M | $-226.30M |
| Income Before Tax | $959.50M | $568.90M | $1.58B | $3.13B | $2.22B |
| Income Before Tax Ratio | 7.38% | 4.68% | 10.64% | 19.39% | 15.88% |
| Income Tax Expense | $212.40M | $188.50M | $302.00M | $747.10M | $662.10M |
| Net Income | $746.00M | $418.00M | $1.28B | $2.38B | $1.56B |
| Net Income Ratio | 5.73% | 3.44% | 8.60% | 14.75% | 11.13% |
| EPS | $8.92 | $4.80 | $14.04 | $24.58 | $15.99 |
| EPS Diluted | $8.86 | $4.77 | $13.96 | $24.38 | $15.88 |
| Weighted Average Shares Outstanding | 83.60M | 87.10M | 91.10M | 96.70M | 97.30M |
| Weighted Average Shares Outstanding Diluted | 84.20M | 87.60M | 91.60M | 97.50M | 98.00M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.35B | $3.33B | $3.28B | $3.22B | $3.18B | $3.03B | $3.06B | $3.03B | $3.78B | $3.67B | $3.61B | $3.70B | $3.90B | $4.06B | $4.06B | $3.84B | $4.16B | $4.49B | $3.90B | $2.77B |
| Cost of Revenue | $2.40B | $2.43B | $2.38B | $2.36B | $2.34B | $2.27B | $2.21B | $2.19B | $2.80B | $2.70B | $2.55B | $2.57B | $2.67B | $2.68B | $2.68B | $2.58B | $2.56B | $2.58B | $2.34B | $2.01B |
| Gross Profit | $948.00M | $896.30M | $904.40M | $864.20M | $837.20M | $762.20M | $851.20M | $842.20M | $974.70M | $969.80M | $1.06B | $1.12B | $1.23B | $1.38B | $1.39B | $1.26B | $1.60B | $1.90B | $1.56B | $760.50M |
| Gross Profit Ratio | 28.34% | 26.92% | 27.56% | 26.83% | 26.36% | 25.13% | 27.85% | 27.76% | 25.80% | 26.39% | 29.39% | 30.37% | 31.62% | 33.90% | 34.10% | 32.93% | 38.42% | 42.43% | 40.02% | 27.47% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $2.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $546.00M | $595.20M | $568.60M | $557.80M | $508.40M | $532.90M | $525.50M | $505.80M | $553.60M | $536.50M | $510.00M | $486.00M | $464.10M | $543.70M | $519.90M | $458.70M | $429.80M | $518.00M | $419.50M | $396.30M |
| Other Expenses | $- | $84.60M | $81.70M | $19.50M | $17.40M | $-73.50M | $21.10M | $-16.90M | $69.30M | $60.60M | $65.20M | $66.40M | $67.10M | $-9.00M | $31.90M | $14.10M | $5.50M | $-9.50M | $-54.20M | $47.70M |
| Operating Expenses | $546.00M | $679.80M | $650.30M | $557.80M | $508.40M | $532.90M | $581.20M | $557.30M | $622.90M | $597.10M | $575.20M | $552.40M | $531.20M | $636.60M | $612.10M | $551.10M | $521.90M | $608.80M | $481.70M | $456.40M |
| Cost and Expenses | $2.94B | $3.11B | $3.03B | $2.91B | $2.85B | $2.80B | $2.79B | $2.75B | $3.43B | $3.30B | $3.12B | $3.13B | $3.20B | $3.32B | $3.29B | $3.13B | $3.08B | $3.19B | $2.82B | $2.46B |
| Interest Income | $- | $- | $- | $- | $- | $6.20M | $15.90M | $4.50M | $2.20M | $1.70M | $4.10M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $-56.00M | $63.40M | $50.40M | $47.60M | $46.90M | $48.80M | $50.30M | $49.80M | $50.70M | $49.30M | $46.30M | $42.50M | $42.20M | $43.10M | $42.20M | $78.30M | $48.50M | $48.30M | $51.40M | $52.70M |
| Depreciation and Amortization | $106.80M | $170.60M | $161.50M | $156.90M | $154.50M | $150.00M | $189.30M | $156.40M | $213.70M | $204.90M | $205.10M | $207.90M | $210.40M | $237.60M | $235.10M | $235.10M | $232.20M | $183.90M | $152.30M | $143.90M |
| EBITDA | $326.00M | $417.80M | $422.50M | $463.30M | $477.50M | $51.70M | $478.30M | $411.20M | $542.20M | $298.70M | $673.00M | $726.80M | $892.70M | $966.70M | $1.05B | $964.00M | $1.30B | $1.52B | $1.24B | $450.50M |
| EBITDA Ratio | 9.75% | 12.55% | 12.87% | 14.38% | 15.03% | 1.70% | 15.65% | 13.55% | 14.35% | 8.13% | 18.66% | 19.66% | 22.89% | 23.83% | 25.73% | 25.10% | 31.30% | 33.95% | 31.73% | 16.27% |
| Operating Income | $326.00M | $216.50M | $254.10M | $306.40M | $328.80M | $229.30M | $252.30M | $266.30M | $341.00M | $374.10M | $469.40M | $525.90M | $687.90M | $730.60M | $766.90M | $704.10M | $1.06B | $1.29B | $1.05B | $297.70M |
| Operating Income Ratio | 9.75% | 6.50% | 7.74% | 9.51% | 10.35% | 7.56% | 8.25% | 8.78% | 9.03% | 10.18% | 13.02% | 14.23% | 17.64% | 18.01% | 18.88% | 18.33% | 25.42% | 28.80% | 26.88% | 10.75% |
| Total Other Income Expenses Net | $-50.80M | $-32.70M | $-43.50M | $-27.10M | $-23.90M | $-24.30M | $-13.60M | $-61.30M | $-63.20M | $-46.20M | $47.60M | $47.60M | $-47.80M | $-44.60M | $1.30M | $-53.50M | $-36.10M | $-50.50M | $-100.00M | $-700.00K |
| Income Before Tax | $275.20M | $183.80M | $210.60M | $267.70M | $297.40M | $-147.10M | $238.70M | $205.00M | $277.80M | $44.50M | $421.60M | $476.40M | $640.10M | $686.00M | $768.20M | $650.60M | $1.02B | $1.24B | $947.10M | $297.00M |
| Income Before Tax Ratio | 8.23% | 5.52% | 6.42% | 8.31% | 9.36% | -4.85% | 7.81% | 6.76% | 7.35% | 1.21% | 11.69% | 12.89% | 16.41% | 16.91% | 18.91% | 16.94% | 24.55% | 27.68% | 24.31% | 10.73% |
| Income Tax Expense | $62.20M | $40.20M | $41.00M | $62.10M | $69.10M | $19.70M | $55.10M | $49.80M | $64.50M | $-31.90M | $68.40M | $117.50M | $148.00M | $132.40M | $180.40M | $182.60M | $251.70M | $304.10M | $243.40M | $65.40M |
| Net Income | $212.80M | $143.40M | $169.30M | $205.30M | $228.00M | $-167.10M | $183.30M | $188.90M | $212.90M | $76.10M | $352.80M | $358.60M | $491.60M | $553.00M | $587.30M | $467.40M | $769.60M | $938.30M | $703.40M | $231.60M |
| Net Income Ratio | 6.36% | 4.31% | 5.16% | 6.37% | 7.18% | -5.51% | 6.00% | 6.23% | 5.64% | 2.07% | 9.78% | 9.70% | 12.61% | 13.63% | 14.46% | 12.17% | 18.49% | 20.90% | 18.05% | 8.36% |
| EPS | $2.54 | $1.72 | $2.02 | $2.44 | $2.71 | $-1.97 | $2.12 | $2.13 | $2.41 | $0.86 | $3.91 | $3.89 | $5.27 | $5.80 | $6.10 | $4.80 | $7.88 | $9.62 | $7.22 | $2.38 |
| EPS Diluted | $2.52 | $1.70 | $2.01 | $2.44 | $2.69 | $-1.97 | $2.11 | $2.12 | $2.39 | $0.86 | $3.89 | $3.87 | $5.23 | $5.75 | $6.05 | $4.76 | $7.82 | $9.54 | $7.17 | $2.37 |
| Weighted Average Shares Outstanding | 83.60M | 83.60M | 84.00M | 84.10M | 84.10M | 84.90M | 86.60M | 88.70M | 88.40M | 88.50M | 90.20M | 92.19M | 93.20M | 95.30M | 96.30M | 97.40M | 97.60M | 97.50M | 97.40M | 97.30M |
| Weighted Average Shares Outstanding Diluted | 84.30M | 84.20M | 84.40M | 84.30M | 84.70M | 84.90M | 87.00M | 89.00M | 89.00M | 89.00M | 90.70M | 92.70M | 94.00M | 96.20M | 97.10M | 98.20M | 98.50M | 98.30M | 98.10M | 97.70M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.52B | $536.80M | $430.00M | $1.47B | $1.32B |
| Short Term Investments | $- | $- | $- | $10.90M | $- |
| Cash and Short Term Investments | $1.52B | $536.80M | $430.00M | $1.47B | $1.32B |
| Net Receivables | $2.10B | $2.10B | $2.00B | $2.98B | $3.02B |
| Inventory | $493.20M | $474.60M | $470.60M | $401.40M | $423.20M |
| Other Current Assets | $697.60M | $655.30M | $2.45B | $478.10M | $364.80M |
| Total Current Assets | $4.81B | $3.77B | $4.62B | $5.33B | $5.13B |
| Property Plant Equipment Net | $3.05B | $2.91B | $2.96B | $2.82B | $2.73B |
| Goodwill | $6.37B | $6.14B | $8.12B | $7.96B | $7.75B |
| Intangible Assets | $3.49B | $3.34B | $3.95B | $3.74B | $3.96B |
| Goodwill and Intangible Assets | $9.86B | $9.48B | $12.07B | $11.69B | $11.71B |
| Long Term Investments | $16.30M | $26.90M | $65.70M | $60.90M | $73.50M |
| Tax Assets | $- | $- | $7.60M | $21.60M | $20.60M |
| Other Non-Current Assets | $652.20M | $536.50M | $432.70M | $462.60M | $410.00M |
| Total Non-Current Assets | $13.57B | $12.96B | $15.53B | $15.05B | $14.95B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $18.38B | $16.73B | $20.16B | $20.39B | $20.07B |
| Account Payables | $875.80M | $827.50M | $852.20M | $621.30M | $638.90M |
| Short Term Debt | $1.19B | $1.17B | $471.10M | $396.50M | $774.10M |
| Tax Payables | $152.70M | $127.50M | $146.10M | $239.60M | $374.80M |
| Deferred Revenue | $392.20M | $421.70M | $582.10M | $558.50M | $506.50M |
| Other Current Liabilities | $718.50M | $676.50M | $1.61B | $967.00M | $784.20M |
| Total Current Liabilities | $3.33B | $3.23B | $3.08B | $2.78B | $3.08B |
| Long Term Debt | $6.08B | $4.78B | $5.78B | $6.14B | $6.18B |
| Deferred Revenue Non-Current | $- | $- | $736.20M | $20.60M | $20.70M |
| Deferred Tax Liabilities Non-Current | $383.10M | $417.90M | $736.20M | $763.40M | $905.40M |
| Other Non-Current Liabilities | $517.40M | $409.30M | $1.19B | $402.00M | $526.40M |
| Total Non-Current Liabilities | $6.98B | $5.61B | $6.98B | $7.33B | $7.63B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $10.31B | $8.83B | $10.06B | $10.11B | $10.71B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $7.60M | $7.70M | $8.10M | $8.50M | $9.00M |
| Retained Earnings | $8.30B | $7.89B | $10.58B | $10.46B | $9.40B |
| Accumulated Other Comprehensive Income Loss | $-261.60M | $-59.30M | $-493.20M | $-192.00M | $-161.90M |
| Other Total Stockholders Equity | $2.80M | $38.40M | $- | $- | $110.30M |
| Total Stockholders Equity | $8.05B | $7.88B | $10.10B | $10.27B | $9.36B |
| Total Equity | $8.07B | $7.89B | $10.12B | $10.29B | $9.38B |
| Total Liabilities and Stockholders Equity | $18.38B | $16.73B | $20.16B | $20.39B | $20.07B |
| Minority Interest | $14.30M | $15.50M | $18.90M | $20.60M | $20.70M |
| Total Liabilities and Total Equity | $18.38B | $16.73B | $20.16B | $20.39B | $20.07B |
| Total Investments | $16.30M | $26.90M | $65.70M | $60.90M | $73.50M |
| Total Debt | $7.27B | $5.95B | $6.29B | $6.34B | $6.76B |
| Net Debt | $5.75B | $5.42B | $5.86B | $4.87B | $5.44B |
Balance Sheet Charts
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $369.40M | $1.52B | $1.52B | $265.10M | $99.30M | $536.80M | $727.90M | $1.93B | $393.90M | $430.00M | $409.90M | $1.07B | $1.23B | $1.47B | $2.04B | $1.96B | $1.89B | $1.32B | $667.20M | $557.00M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $10.90M | $18.50M | $800.00K | $- | $- | $- | $2.30M |
| Cash and Short Term Investments | $369.40M | $1.52B | $1.52B | $265.10M | $99.30M | $536.80M | $727.90M | $1.93B | $393.90M | $430.00M | $409.90M | $1.07B | $1.23B | $1.47B | $2.04B | $1.96B | $1.89B | $1.32B | $667.20M | $557.00M |
| Net Receivables | $2.12B | $2.10B | $2.22B | $2.25B | $2.20B | $2.10B | $2.06B | $2.04B | $3.05B | $2.22B | $2.98B | $3.04B | $3.04B | $2.98B | $3.06B | $2.85B | $2.90B | $3.02B | $2.70B | $2.20B |
| Inventory | $488.30M | $493.20M | $483.10M | $441.80M | $475.00M | $474.60M | $461.10M | $487.80M | $481.40M | $470.60M | $467.70M | $436.30M | $440.70M | $401.40M | $410.70M | $421.30M | $427.50M | $423.20M | $392.50M | $342.30M |
| Other Current Assets | $808.80M | $697.60M | $684.70M | $618.00M | $678.10M | $655.30M | $700.20M | $659.90M | $769.80M | $1.50B | $511.50M | $481.90M | $515.70M | $478.10M | $518.30M | $461.90M | $416.80M | $364.80M | $327.20M | $317.50M |
| Total Current Assets | $3.79B | $4.81B | $4.91B | $3.57B | $3.46B | $3.77B | $3.95B | $5.12B | $4.70B | $4.62B | $4.37B | $5.03B | $5.23B | $5.33B | $6.02B | $5.69B | $5.64B | $5.13B | $4.09B | $3.41B |
| Property Plant Equipment Net | $3.09B | $3.05B | $3.05B | $2.93B | $2.90B | $2.91B | $2.82B | $2.76B | $2.94B | $2.96B | $2.88B | $2.87B | $2.81B | $2.82B | $2.69B | $2.70B | $2.70B | $2.73B | $2.61B | $2.63B |
| Goodwill | $6.42B | $6.37B | $6.48B | $6.22B | $6.22B | $6.14B | $6.33B | $6.17B | $8.12B | $8.12B | $8.22B | $8.11B | $8.17B | $7.96B | $7.91B | $7.74B | $7.72B | $7.75B | $7.61B | $7.42B |
| Intangible Assets | $3.49B | $3.49B | $3.54B | $3.33B | $3.39B | $3.34B | $3.28B | $3.15B | $3.91B | $3.95B | $3.81B | $3.86B | $3.97B | $3.74B | $3.76B | $3.75B | $3.83B | $3.96B | $3.92B | $3.88B |
| Goodwill and Intangible Assets | $9.91B | $9.86B | $10.02B | $9.55B | $9.61B | $9.48B | $9.61B | $9.32B | $12.03B | $12.07B | $12.03B | $11.98B | $12.14B | $11.69B | $11.66B | $11.50B | $11.55B | $11.71B | $11.53B | $11.30B |
| Long Term Investments | $168.00M | $16.30M | $16.90M | $17.50M | $17.70M | $26.90M | $39.50M | $67.20M | $65.80M | $65.70M | $63.70M | $57.70M | $62.20M | $60.90M | $62.10M | $82.10M | $85.00M | $73.50M | $70.70M | $72.30M |
| Tax Assets | $- | $- | $358.30M | $376.10M | $397.20M | $417.90M | $7.70M | $6.40M | $7.70M | $7.60M | $29.40M | $28.70M | $28.20M | $21.60M | $23.80M | $23.70M | $20.20M | $20.60M | $3.40M | $4.90M |
| Other Non-Current Assets | $647.00M | $652.20M | $254.30M | $262.70M | $148.80M | $118.60M | $456.60M | $425.80M | $459.10M | $432.70M | $451.00M | $436.80M | $462.60M | $462.60M | $406.00M | $417.70M | $422.30M | $410.00M | $437.00M | $431.10M |
| Total Non-Current Assets | $13.81B | $13.57B | $13.70B | $13.14B | $13.07B | $12.96B | $12.93B | $12.58B | $15.51B | $15.53B | $15.45B | $15.37B | $15.50B | $15.05B | $14.85B | $14.72B | $14.78B | $14.95B | $14.65B | $14.44B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- |
| Total Assets | $17.60B | $18.38B | $18.61B | $16.71B | $16.53B | $16.73B | $16.89B | $17.71B | $20.20B | $20.16B | $19.83B | $20.40B | $20.73B | $20.39B | $20.87B | $20.42B | $20.42B | $20.07B | $18.74B | $17.85B |
| Account Payables | $717.90M | $875.80M | $660.90M | $760.60M | $695.50M | $827.50M | $690.60M | $713.10M | $880.70M | $852.20M | $765.50M | $754.70M | $623.60M | $621.30M | $669.40M | $599.90M | $621.30M | $638.90M | $639.50M | $534.10M |
| Short Term Debt | $188.00M | $1.38B | $1.59B | $2.40B | $2.40B | $1.34B | $1.33B | $624.00M | $676.00M | $662.60M | $368.50M | $406.80M | $401.40M | $396.50M | $401.00M | $403.40M | $896.60M | $575.40M | $779.00M | $1.20B |
| Tax Payables | $- | $152.70M | $- | $- | $- | $127.50M | $- | $- | $- | $146.10M | $- | $- | $- | $239.60M | $- | $- | $- | $374.80M | $- | $- |
| Deferred Revenue | $388.30M | $392.20M | $403.10M | $388.30M | $377.50M | $421.70M | $360.80M | $349.70M | $586.70M | $582.10M | $530.90M | $544.20M | $556.00M | $558.50M | $593.90M | $546.70M | $540.30M | $506.50M | $494.80M | $473.30M |
| Other Current Liabilities | $770.40M | $527.80M | $757.50M | $518.70M | $293.90M | $504.30M | $521.00M | $496.50M | $742.20M | $835.50M | $857.40M | $937.20M | $1.06B | $967.00M | $1.22B | $1.12B | $1.31B | $982.90M | $1.10B | $829.20M |
| Total Current Liabilities | $2.06B | $3.33B | $3.41B | $4.06B | $3.94B | $3.23B | $2.90B | $2.18B | $2.89B | $3.08B | $2.52B | $2.64B | $2.64B | $2.78B | $2.89B | $2.67B | $3.37B | $3.08B | $3.01B | $3.03B |
| Long Term Debt | $6.33B | $750.60M | $6.13B | $3.77B | $3.75B | $4.78B | $5.17B | $5.75B | $5.80B | $5.78B | $6.09B | $6.11B | $6.09B | $6.14B | $6.13B | $6.16B | $5.66B | $6.18B | $6.11B | $6.12B |
| Deferred Revenue Non-Current | $- | $- | $- | $719.50M | $701.70M | $727.50M | $- | $- | $- | $736.20M | $672.70M | $743.40M | $- | $762.90M | $20.60M | $21.00M | $20.90M | $905.40M | $19.90M | $19.50M |
| Deferred Tax Liabilities Non-Current | $388.00M | $383.10M | $358.30M | $376.10M | $397.20M | $417.90M | $499.50M | $564.50M | $737.40M | $736.20M | $672.70M | $743.40M | $765.20M | $763.40M | $804.80M | $826.00M | $857.70M | $905.40M | $891.50M | $907.30M |
| Other Non-Current Liabilities | $497.90M | $5.85B | $528.20M | $483.90M | $468.20M | $409.30M | $423.00M | $418.50M | $413.60M | $449.60M | $433.90M | $484.50M | $489.80M | $402.00M | $494.00M | $502.90M | $486.90M | $624.00M | $473.20M | $415.60M |
| Total Non-Current Liabilities | $7.22B | $6.98B | $7.02B | $4.63B | $4.61B | $5.61B | $6.09B | $6.73B | $6.95B | $6.98B | $7.21B | $7.36B | $7.37B | $7.33B | $7.45B | $7.50B | $7.03B | $7.63B | $7.49B | $7.46B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $- |
| Total Liabilities | $9.28B | $10.31B | $10.43B | $8.69B | $8.56B | $8.83B | $8.99B | $8.91B | $9.84B | $10.06B | $9.73B | $10.00B | $10.01B | $10.11B | $10.34B | $10.17B | $10.40B | $10.71B | $10.50B | $10.50B |
| Preferred Stock | $- | $- | $1 | $171.40M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $7.60M | $7.60M | $7.60M | $7.70M | $7.70M | $7.70M | $7.70M | $8.10M | $8.10M | $8.10M | $8.20M | $8.30M | $8.50M | $8.50M | $8.80M | $8.90M | $9.00M | $9.00M | $9.00M | $9.00M |
| Retained Earnings | $8.46B | $8.30B | $8.28B | $8.18B | $8.06B | $7.89B | $8.07B | $8.82B | $10.73B | $10.58B | $10.85B | $10.90B | $10.95B | $10.46B | $10.79B | $10.42B | $10.17B | $9.40B | $8.46B | $7.76B |
| Accumulated Other Comprehensive Income Loss | $-191.60M | $-261.60M | $-113.20M | $-192.00M | $-185.40M | $-59.30M | $-208.80M | $-153.70M | $-444.20M | $-493.20M | $-761.00M | $-505.50M | $-264.90M | $-192.00M | $-270.90M | $-181.20M | $-226.50M | $-161.90M | $-314.60M | $-449.00M |
| Other Total Stockholders Equity | $35.80M | $2.80M | $-1 | $12.50M | $82.00M | $38.40M | $4.70M | $94.40M | $47.70M | $- | $- | $- | $29.10M | $- | $- | $- | $67.10M | $187.20M | $80.70M | $32.10M |
| Total Stockholders Equity | $8.31B | $8.05B | $8.17B | $8.01B | $7.96B | $7.88B | $7.87B | $8.77B | $10.34B | $10.10B | $10.09B | $10.40B | $10.72B | $10.27B | $10.52B | $10.25B | $10.02B | $9.36B | $8.24B | $7.35B |
| Total Equity | $8.32B | $8.07B | $8.19B | $8.02B | $7.97B | $7.89B | $7.89B | $8.79B | $10.36B | $10.12B | $10.11B | $10.42B | $10.74B | $10.29B | $10.55B | $10.27B | $10.04B | $9.38B | $8.26B | $7.37B |
| Total Liabilities and Stockholders Equity | $17.60B | $18.38B | $18.61B | $16.71B | $16.53B | $16.73B | $16.89B | $17.71B | $20.20B | $20.16B | $19.83B | $20.40B | $20.73B | $20.39B | $20.87B | $20.42B | $20.42B | $20.07B | $18.74B | $17.85B |
| Minority Interest | $14.30M | $14.30M | $15.20M | $15.00M | $15.20M | $15.50M | $19.40M | $19.80M | $19.30M | $18.90M | $18.90M | $20.00M | $20.60M | $20.60M | $20.60M | $21.00M | $20.90M | $20.70M | $19.90M | $19.50M |
| Total Liabilities and Total Equity | $17.60B | $18.38B | $18.61B | $16.71B | $16.53B | $16.73B | $16.89B | $17.71B | $20.20B | $20.16B | $19.83B | $20.40B | $20.73B | $20.39B | $20.87B | $20.42B | $20.42B | $20.07B | $18.74B | $17.85B |
| Total Investments | $168.00M | $16.30M | $16.90M | $17.50M | $17.70M | $26.90M | $39.50M | $67.20M | $65.80M | $65.70M | $63.70M | $57.70M | $62.20M | $60.90M | $62.10M | $82.10M | $85.00M | $73.50M | $70.70M | $72.30M |
| Total Debt | $6.52B | $1.94B | $7.72B | $5.98B | $5.97B | $5.95B | $6.33B | $6.21B | $6.29B | $6.29B | $6.27B | $6.32B | $6.29B | $6.34B | $6.34B | $6.36B | $6.36B | $6.76B | $6.68B | $7.11B |
| Net Debt | $6.15B | $422.90M | $6.20B | $5.71B | $5.87B | $5.42B | $5.60B | $4.28B | $5.90B | $5.86B | $5.86B | $5.25B | $5.06B | $4.87B | $4.30B | $4.39B | $4.47B | $5.44B | $6.02B | $6.56B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $746.50M | $379.20M | $1.28B | $2.38B | $1.56B |
| Depreciation and Amortization | $643.50M | $577.30M | $633.90M | $745.10M | $624.70M |
| Deferred Income Tax | $-20.10M | $-78.10M | $18.30M | $-75.90M | $-47.00M |
| Stock Based Compensation | $116.70M | $128.70M | $116.80M | $132.90M | $111.70M |
| Change in Working Capital | $-154.10M | $-361.90M | $-603.40M | $-263.70M | $-856.90M |
| Accounts Receivables | $98.50M | $-75.30M | $15.90M | $222.00M | $-913.40M |
| Inventory | $-14.60M | $-700.00K | $-45.50M | $2.80M | $-196.60M |
| Accounts Payables | $210.30M | $-42.40M | $307.10M | $-10.20M | $-5.30M |
| Other Working Capital | $-448.30M | $-243.50M | $-880.90M | $-478.30M | $258.40M |
| Other Non Cash Items | $253.30M | $682.50M | $482.40M | $170.90M | $745.80M |
| Net Cash Provided by Operating Activities | $1.59B | $1.33B | $1.96B | $3.11B | $2.14B |
| Investments in Property Plant and Equipment | $-489.90M | $-453.60M | $-481.90M | $-460.40M | $-381.70M |
| Acquisitions Net | $-823.90M | $-671.50M | $-1.16B | $-496.90M | $-267.60M |
| Purchases of Investments | $-55.00M | $-29.00M | $-17.40M | $-27.80M | $-40.10M |
| Sales Maturities of Investments | $- | $6.70M | $8.10M | $13.20M | $4.10M |
| Other Investing Activities | $2.00M | $-24.10M | $1.40M | $87.30M | $42.10M |
| Net Cash Used for Investing Activities | $-1.37B | $-1.17B | $-1.65B | $-884.60M | $-643.20M |
| Debt Repayment | $1.00B | $-300.00M | $- | $-375.00M | $-412.20M |
| Common Stock Issued | $- | $- | $50.60M | $51.70M | $55.90M |
| Common Stock Repurchased | $-250.10M | $-1.00B | $-1.10B | $-1.67B | $-100.00M |
| Dividends Paid | $-243.10M | $-254.00M | $-195.20M | $- | $- |
| Other Financing Activities | $273.10M | $1.49B | $-27.00M | $-22.30M | $-5.20M |
| Net Cash Used Provided by Financing Activities | $779.90M | $-59.30M | $-1.32B | $-2.07B | $-517.40M |
| Effect of Forex Changes on Cash | $-17.00M | $9.90M | $-24.20M | $-7.30M | $8.60M |
| Net Change in Cash | $981.90M | $216.20M | $-1.04B | $151.90M | $983.30M |
| Cash at End of Period | $1.52B | $536.80M | $430.00M | $1.47B | $1.32B |
| Cash at Beginning of Period | $536.80M | $320.60M | $1.47B | $1.32B | $337.50M |
| Operating Cash Flow | $1.59B | $1.33B | $1.96B | $3.11B | $2.14B |
| Capital Expenditure | $-489.90M | $-453.60M | $-481.90M | $-460.40M | $-381.70M |
| Free Cash Flow | $1.10B | $874.10M | $1.47B | $2.65B | $1.75B |
Cash Flow Charts
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $213.00M | $143.60M | $169.60M | $205.30M | $228.00M | $-167.10M | $183.60M | $155.00M | $213.30M | $76.40M | $353.20M | $358.90M | $492.10M | $553.60M | $587.80M | $468.00M | $770.10M | $938.60M | $703.70M | $231.60M |
| Depreciation and Amortization | $166.80M | $170.60M | $161.50M | $156.90M | $154.50M | $150.00M | $145.90M | $142.80M | $165.90M | $156.20M | $157.10M | $159.10M | $161.50M | $188.00M | $186.10M | $187.10M | $183.90M | $183.90M | $152.30M | $143.90M |
| Deferred Income Tax | $-6.10M | $38.50M | $-19.50M | $-19.60M | $-19.50M | $-59.90M | $-34.40M | $13.90M | $1.80M | $69.90M | $-16.10M | $-16.50M | $-19.00M | $26.10M | $-16.50M | $-57.70M | $-27.80M | $1.50M | $-19.10M | $-34.50M |
| Stock Based Compensation | $32.80M | $27.30M | $27.00M | $30.80M | $31.60M | $27.00M | $34.40M | $34.40M | $32.90M | $30.20M | $36.30M | $39.40M | $38.20M | $42.10M | $59.00M | $23.90M | $28.70M | $26.80M | $27.20M | $39.80M |
| Change in Working Capital | $- | $329.70M | $-118.80M | $103.30M | $-468.30M | $224.60M | $-108.40M | $-107.40M | $-356.20M | $-19.50M | $-196.10M | $-24.50M | $-363.30M | $-178.90M | $-54.80M | $-187.60M | $157.60M | $-455.20M | $-148.00M | $-68.90M |
| Accounts Receivables | $-170.80M | $98.50M | $45.00M | $-42.20M | $-123.20M | $-5.10M | $-66.00M | $-100.00K | $-117.50M | $-35.90M | $30.40M | $1.00M | $20.40M | $86.40M | $-129.40M | $118.30M | $146.70M | $-366.50M | $-422.70M | $-170.90M |
| Inventory | $8.40M | $-14.60M | $-25.70M | $28.30M | $-600.00K | $-10.40M | $25.80M | $-19.50M | $-10.00M | $2.00M | $-11.80M | $1.70M | $-37.40M | $9.30M | $11.00M | $-12.80M | $-4.70M | $-49.10M | $-49.10M | $-87.80M |
| Accounts Payables | $-147.60M | $210.30M | $-86.50M | $69.40M | $-121.10M | $146.20M | $-28.30M | $-117.40M | $-56.40M | $172.00M | $3.20M | $137.40M | $-5.50M | $-44.80M | $78.90M | $-27.40M | $-16.90M | $-22.60M | $106.20M | $-32.40M |
| Other Working Capital | $- | $35.50M | $-51.60M | $47.80M | $-223.40M | $93.90M | $-39.90M | $29.60M | $-172.30M | $-157.60M | $-217.90M | $-164.60M | $-340.80M | $-229.80M | $-15.30M | $-265.70M | $32.50M | $-17.00M | $217.60M | $222.20M |
| Other Non Cash Items | $-388.00M | $67.50M | $57.50M | $373.50M | $629.40M | $405.00M | $54.40M | $112.70M | $55.80M | $340.40M | $39.40M | $56.10M | $46.50M | $66.60M | $5.70M | $53.50M | $45.10M | $79.00M | $70.10M | $58.80M |
| Net Cash Provided by Operating Activities | $18.50M | $777.20M | $277.30M | $561.10M | $-29.80M | $579.60M | $275.50M | $351.40M | $121.20M | $653.60M | $373.80M | $572.50M | $356.00M | $697.50M | $767.30M | $487.20M | $1.16B | $774.60M | $786.20M | $370.70M |
| Investments in Property Plant and Equipment | $-126.00M | $-112.10M | $-115.80M | $-128.20M | $-133.80M | $-167.20M | $-104.90M | $-102.60M | $-93.90M | $-117.90M | $-103.50M | $-143.30M | $-117.20M | $-150.00M | $-117.80M | $-97.20M | $-95.40M | $-99.40M | $-77.20M | $-98.50M |
| Acquisitions Net | $-53.50M | $-43.90M | $-463.70M | $-33.80M | $-245.60M | $-154.50M | $-389.50M | $-141.40M | $-5.90M | $-148.80M | $-460.10M | $-102.30M | $-457.30M | $-170.90M | $-300.70M | $6.70M | $-39.60M | $-58.80M | $-211.30M | $-25.20M |
| Purchases of Investments | $- | $- | $- | $-23.00M | $-13.70M | $-8.90M | $-9.70M | $-4.30M | $-6.10M | $-11.30M | $-100.00K | $-2.50M | $-2.20M | $-20.20M | $-8.10M | $-6.40M | $-5.50M | $-10.80M | $77.20M | $98.50M |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $165.20M | $6.70M | $4.30M | $6.10M | $4.50M | $300.00K | $3.00M | $400.00K | $2.80M | $10.40M | $- | $- | $-3.10M | $3.10M | $100.00K |
| Other Investing Activities | $-156.50M | $-53.60M | $400.00K | $100.00K | $100.00K | $-165.20M | $9.80M | $-9.60M | $100.00K | $200.00K | $100.00K | $2.60M | $1.00M | $83.80M | $800.00K | $100.00K | $2.60M | $44.10M | $-77.00M | $-98.30M |
| Net Cash Used for Investing Activities | $-336.00M | $-209.60M | $-579.10M | $-185.00M | $-393.10M | $-330.60M | $-487.60M | $-253.60M | $-99.70M | $-273.30M | $-563.30M | $-242.50M | $-573.10M | $-254.50M | $-407.30M | $-90.40M | $-132.40M | $-128.00M | $-285.20M | $-123.40M |
| Debt Repayment | $- | $-400.00M | $1.38B | $-22.60M | $42.40M | $-389.60M | $- | $- | $- | $- | $- | $- | $- | $-1.00B | $- | $- | $-375.00M | $- | $-412.20M | $- |
| Common Stock Issued | $-25.50M | $- | $- | $-23.10M | $26.70M | $- | $- | $26.80M | $27.60M | $- | $31.50M | $900.00K | $18.20M | $900.00K | $24.20M | $1.90M | $24.70M | $5.30M | $21.80M | $1.90M |
| Common Stock Repurchased | $- | $-75.10M | $-75.00M | $-100.00M | $- | $9.00M | $-1.01B | $- | $- | $-300.00M | $-400.00M | $-400.00M | $- | $-1.00B | $-300.00M | $-300.00M | $-68.50M | $-2.50M | $-500.00K | $-9.50M |
| Dividends Paid | $-61.60M | $-60.10M | $-60.50M | $-60.40M | $-62.10M | $-61.10M | $-63.90M | $-64.60M | $-64.40M | $-63.60M | $-64.90M | $-66.70M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-778.10M | $-11.50M | $303.60M | $-27.00M | $-18.70M | $-4.80M | $-24.30M | $1.58B | $-23.80M | $-9.00M | $12.70M | $-13.90M | $-35.90M | $991.40M | $18.30M | $-25.40M | $-6.60M | $1.50M | $-6.30M | $-16.90M |
| Net Cash Used Provided by Financing Activities | $-839.70M | $-546.70M | $1.55B | $-210.00M | $-11.70M | $-446.50M | $-987.80M | $1.54B | $-60.60M | $-372.60M | $-452.20M | $-479.70M | $-17.70M | $-1.01B | $-281.70M | $-325.40M | $-450.10M | $-1.00M | $-396.70M | $-16.90M |
| Effect of Forex Changes on Cash | $7.90M | $-19.50M | $5.70M | $-300.00K | $-2.90M | $6.40M | $-2.80M | $3.30M | $3.00M | $12.40M | $-17.20M | $-15.00M | $-4.40M | $1.80M | $-5.00M | $1.00M | $-5.10M | $8.00M | $5.90M | $3.00M |
| Net Change in Cash | $-1.15B | $1.40M | $1.25B | $165.80M | $-437.50M | $-191.10M | $-1.20B | $1.54B | $-36.10M | $20.10M | $-658.90M | $-164.70M | $-239.20M | $-563.80M | $73.30M | $72.40M | $570.00M | $653.60M | $110.20M | $233.40M |
| Cash at End of Period | $369.40M | $1.52B | $1.52B | $265.10M | $99.30M | $536.80M | $727.90M | $1.93B | $393.90M | $430.00M | $409.90M | $1.07B | $1.23B | $1.47B | $2.04B | $1.96B | $1.89B | $1.32B | $667.20M | $557.00M |
| Cash at Beginning of Period | $1.52B | $1.52B | $265.10M | $99.30M | $536.80M | $727.90M | $1.93B | $393.90M | $430.00M | $409.90M | $1.07B | $1.23B | $1.47B | $2.04B | $1.96B | $1.89B | $1.32B | $667.20M | $557.00M | $323.60M |
| Operating Cash Flow | $18.50M | $777.20M | $277.30M | $561.10M | $-29.80M | $579.60M | $275.50M | $351.40M | $121.20M | $653.60M | $373.80M | $572.50M | $356.00M | $697.50M | $767.30M | $487.20M | $1.16B | $774.60M | $786.20M | $370.70M |
| Capital Expenditure | $-126.00M | $-112.10M | $-115.80M | $-128.20M | $-133.80M | $-167.20M | $-104.90M | $-102.60M | $-93.90M | $-117.90M | $-103.50M | $-143.30M | $-117.20M | $-150.00M | $-117.80M | $-97.20M | $-95.40M | $-99.40M | $-77.20M | $-98.50M |
| Free Cash Flow | $-107.50M | $665.10M | $161.50M | $432.90M | $-163.60M | $412.40M | $170.60M | $248.80M | $27.30M | $535.70M | $270.30M | $429.20M | $238.80M | $547.50M | $649.50M | $390.00M | $1.06B | $675.20M | $709.00M | $272.20M |
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
$240.42
Stock Price
$20.12B
Market Cap
70.00K
Employees
Burlington, NC
Location
Revenue (FY 2024)
$13.01B
7.0% YoY
Net Income (FY 2024)
$746.00M
78.5% YoY
EPS (FY 2024)
$8.86
85.7% YoY
Free Cash Flow (FY 2024)
$1.10B
25.4% YoY
Profitability
Gross Margin
26.9%
Net Margin
5.7%
ROE
9.3%
ROA
4.1%
Valuation
P/E Ratio
25.70
P/S Ratio
1.47
EV/EBITDA
13.76
Market Cap
$20.12B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$1.59B
19.4% YoY
Free Cash Flow
$1.10B
25.4% YoY
Balance Sheet Summary
Total Assets
$18.38B
9.9% YoY
Total Debt
$7.27B
22.1% YoY
Shareholder Equity
$8.05B
6.5% YoY
Dividend Overview
$0.72
Latest Dividend
%
Dividend Yield
%
Payout Ratio
Recent Dividend History
| Date | Amount | Type |
|---|---|---|
| 2025-05-29 | $0.72 | May 29, 25 |
| 2025-02-27 | $0.72 | February 27, 25 |
| 2024-11-26 | $0.72 | November 26, 24 |
| 2024-08-29 | $0.72 | August 29, 24 |
| 2024-05-24 | $0.72 | May 24, 24 |
| 2024-02-26 | $0.72 | February 26, 24 |
| 2023-11-07 | $0.72 | November 07, 23 |
| 2023-08-07 | $0.72 | August 07, 23 |
| 2023-05-17 | $0.72 | May 17, 23 |
| 2023-02-22 | $0.72 | February 22, 23 |
Laboratory of America Holdings Dividends
Explore Laboratory of America Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
1.27%
Dividend Payout Ratio
32.59%
Dividend Paid & Capex Coverage Ratio
2.16x
Laboratory of America Holdings Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.72 | $0.72 | May 29, 2025 | May 29, 2025 | June 11, 2025 | April 10, 2025 |
| $0.72 | $0.72 | February 27, 2025 | February 27, 2025 | March 12, 2025 | January 08, 2025 |
| $0.72 | $0.72 | November 26, 2024 | November 26, 2024 | December 13, 2024 | October 10, 2024 |
| $0.72 | $0.72 | August 29, 2024 | August 29, 2024 | September 13, 2024 | July 25, 2024 |
| $0.72 | $0.72 | May 24, 2024 | May 28, 2024 | June 12, 2024 | April 11, 2024 |
| $0.72 | $0.72 | February 26, 2024 | February 27, 2024 | March 13, 2024 | January 12, 2024 |
| $0.72 | $0.72 | November 07, 2023 | November 08, 2023 | December 12, 2023 | October 12, 2023 |
| $0.72 | $0.72 | August 07, 2023 | August 08, 2023 | September 08, 2023 | July 13, 2023 |
| $0.72 | $0.61856 | May 17, 2023 | May 18, 2023 | June 08, 2023 | April 06, 2023 |
| $0.72 | $0.61856 | February 22, 2023 | February 23, 2023 | March 13, 2023 | January 12, 2023 |
| $0.72 | $0.61856 | November 16, 2022 | November 17, 2022 | December 09, 2022 | October 12, 2022 |
| $0.72 | $0.61856 | August 17, 2022 | August 18, 2022 | September 09, 2022 | July 14, 2022 |
| $0.72 | $0.61856 | May 18, 2022 | May 19, 2022 | June 09, 2022 | April 07, 2022 |
| $0.08 | $0.17182 | March 29, 1994 | April 05, 1994 | April 26, 1994 | |
| $0.08 | $0.17182 | December 29, 1993 | January 04, 1994 | January 25, 1994 | |
| $0.08 | $0.17182 | September 29, 1993 | October 05, 1993 | October 26, 1993 | |
| $0.08 | $0.17182 | June 29, 1993 | July 06, 1993 | July 27, 1993 | |
| $0.08 | $0.17182 | March 31, 1993 | April 06, 1993 | April 27, 1993 | |
| $0.08 | $0.17182 | December 29, 1992 | January 05, 1993 | January 26, 1993 | |
| $0.08 | $0.17182 | September 28, 1992 | October 02, 1992 | October 23, 1992 |
Laboratory of America Holdings News
Read the latest news about Laboratory of America Holdings, including recent articles, headlines, and updates.
Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Christin O'Donnell - Investor Relations Adam Schechter - Chairman & Chief Executive Officer Julia Wang - Executive Vice President & Chief Financial Officer Conference Call Participants Michael Cherny - Leerink Partners Ann Hynes - Mizuho Securities Erin Wright - Morgan Stanley Elizabeth Anderson - Evercore ISI Lisa Gill - JPMorgan Jack Meehan - Nephron Research Luke Sergott - Barclays Kevin Caliendo - UBS Michael Ryskin - Bank of America Patrick Donnelly - Citi Eric Coldwell - Baird Kieran Ryan - Deutsche Bank Operator Good day and thank you for standing by. Welcome to the Q1 2025 Labcorp Holdings Earnings Conference Call.
Labcorp (LH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp Announces 2025 First Quarter Results
Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 Free Cash Flow of $1.10 billion to $1.25 billion Providing broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-date Introduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid in the diagnosis of Alzheimer's disease BURLINGTON, N.C. , April 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance.
Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now available to support treatment selection BURLINGTON, N.C. , April 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio with two solutions: Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients, and the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from targeted treatments.
Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics
Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The market for genetic screening testing in preventive health has been experiencing rapid growth, driven by driving factors such as technological advancements, increased consumer interest in personalized medicine, and the rise of preventive healthcare strategies. Several key factors influence the expansion of the genetic screening testing for preventive health market. Improvements in genetic testing technologies, such as next-generation sequencing (NGS), have made these tests more accessible, cost-effective, and accurate. Growing consumer awareness of the benefits of early detection, rising healthcare costs, and an increasing focus on prevention have further fuelled the demand. Moreover, the increasing availability of direct-to-consumer genetic tests has allowed individuals to manage their health. Stakeholders in this market include genetic testing companies, healthcare providers, hospitals, diagnostic laboratories, and wellness-focused organizations. As more people seek personalized, data-driven approaches to healthcare, the demand for genetic screenings as a preventive tool is expected to increase. Moreover, the growing availability of direct-to-consumer genetic testing kits has empowered individuals to take charge of their health and gain insights into their genetic predispositions without necessarily needing a healthcare provider. This trend has significantly expanded the genetic screening market, allowing consumers to access preventive health information more easily. The genetic screening testing for preventive health market is set to witness substantial growth. With continued technological advancements and growing public interest in health optimization and disease prevention, the market offers significant opportunities for healthcare, biotechnology, and wellness stakeholders to meet the rising demand for personalized, proactive health solutions. The development of next-generation sequencing (NGS) technologies and improvements in bioinformatics have made genetic testing more accurate, efficient, and affordable. These innovations allow for comprehensive genetic analysis, enhancing the ability to detect predispositions to various diseases at earlier stages. The continuous evolution of these technologies further drives the demand for genetic screening services in preventive healthcare. Furthermore, there is a growing recognition of the importance of preventive healthcare, with more individuals understanding the benefits of early disease detection and management. Public health campaigns, medical professionals, and organizations have been emphasizing the value of genetic screening to detect health risks before symptoms appear, further driving market demand.
Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease.
Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide
New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C. , April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the risk of developing cervical cancer.
Labcorp to Announce First Quarter Financial Results on April 29, 2025
BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2025 before the market opens on Tuesday, April 29, 2025.
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors
Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C. , Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM , a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors.
Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'
Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects.
Are Investors Undervaluing Labcorp (LH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Christian O'Donnell - IR Adam Schechter - Chairman and CEO Julia Wang - EVP and CFO Conference Call Participants Michael Cherny - Leerink Partners Jack Meehan - Nephron Research Lisa Gill - JP Morgan Erin Wright - Morgan Stanley Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Patrick Donnelly - Citi Kevin Caliendo - UBS David Westenberg - Piper Sandler Tycho Peterson - Jefferies Operator Good day, and thank you for standing by. Welcome to Labcorp's Fourth Quarter 2024 Conference Call [Operator Instructions].
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LH.